Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor

2019-07-17 10:04:57 | BioPortfolio


The study will compare 2 treatment modalities. One group will receive the routine protocol of intermittent pitocin induction for 6 hours and the second group will receive continous pitocin infusion.

The primary aim is to observe which protocol leads to the fastest delivery and evaluate the time in each group from induction to delivery.


At enrollment, after consenting to participate in the study, patients will be assigned randomly to either routine oxytocin (intermittent) treatment or continuous oxytocin treatment.

Both groups will follow our institutional oxytocin protocol. The primary dose of oxytocin is 2.0 mU/min, with an incremental increase by 5.0 mU/min every 30 minutes, until 40.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation > 6 cm). Women will be continuously monitored to fetal heart rate while oxytocin is administered.

In the intermittent group, oxytocin will be discontinued after 6-8 hours if the patient does not go into active labor in that period of time. The second course of oxytocin will be renewed after 8-12 hours. In the continuous group, women will receive a continuous oxytocin infusion until delivery, unless there is an indication to stop the infusion, including; category II fetal tracing, uterine tachysystole (an average of more than 5 contractions in 10 minutes for more than 30 minutes).

During oxytocin infusion, sodium levels will be monitored every four hours. In cases where the maternal sodium is below 125 mmol/L oxytocin should be stopped. The decision regarding further oxytocin administration should be made following assessment of the woman's clinical condition and circumstances after discussion with a consultant obstetrician.

Study Design


Induced; Birth


Oxytocin, Oxytocin


Not yet recruiting


Rambam Health Care Campus

Results (where available)

View Results


Published on BioPortfolio: 2019-07-17T10:04:57-0400

Clinical Trials [1160 Associated Clinical Trials listed on BioPortfolio]

IV Versus IM Administration of Oxytocin for Postpartum Bleeding

This double-blind, randomized controlled trial will evaluate the effect of the route of administration of 10 IU of oxytocin on the average blood loss postpartum. Participants will be rando...

Oxytocin Administration in the Third Stage of Labour - A Study of Appropriate Route and Dose

Mothers are given the medication oxytocin after birth to help the uterus (womb) contract and therefore reduce blood loss. In Canada, oxytocin is given either into the muscle of the thigh o...

Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women

The study will evaluate a stable, dry-powder formulation of oxytocin, with the goal of reducing post-partum hemorrhage morbidity and mortality in resource poor settings. This study is bein...

Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor

The overall purpose of this study is to determine if adding oxytocin to a Foley catheter for induction of labor will increase the rate of delivery within 24 hours stratified by parity.

Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers

The aim of this study is to determine if oxytocin administration is able to blunt LPS induced increase of cytokines (TNF-α) and if there is a change in the endocrine response after lipopo...

PubMed Articles [10781 Associated PubMed Articles listed on BioPortfolio]

Effects of Intranasal Oxytocin on Tactile Perception.

In addition to its role in childbirth labor and lactation, oxytocin is a well-known neurohormone, having several prosocial effects. Moreover, oxytocin seems to play a significant modulatory role in pa...

Challenges for measuring oxytocin: The blind men and the elephant?

Since its discovery more than a century ago, oxytocin has become one of the most intensively studied molecules in behavioral biology. In the last five years, Psychoneuroendocrinology has published mor...

New Metabolic Influencer on Oxytocin Release: The Ghrelin.

The hypothalamic⁻pituitary axis by secreting neuropeptides plays a key role in metabolic homeostasis. In light of the metabolic regulation, oxytocin is a potential neuropeptide for therapies against...

Systemic Oxytocin Administration Alters Mesolimbic Dopamine Release in Mice.

Growing research indicates oxytocin may be involved in relieving anxiety and attenuating the rewarding effects of psychostimulants. This study investigated the effects of subchronic oxytocin treatment...

Intranasal administration of oxytocin decreases task-related aggressive responses in healthy young males.

Aggression and distrust are often challenging problems in mental health treatment. Converging evidence reveals that oxytocin increases trust in social interactions and decreases fear of social betraya...

Medical and Biotech [MESH] Definitions

Cell surface proteins that bind oxytocin with high affinity and trigger intracellular changes which influence the behavior of cells. Oxytocin receptors in the uterus and the mammary glands mediate the hormone's stimulation of contraction and milk ejection. The presence of oxytocin and oxytocin receptors in neurons of the brain probably reflects an additional role as a neurotransmitter.

A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.

Carrier proteins for OXYTOCIN and VASOPRESSIN. They are polypeptides of about 10-kDa, synthesized in the HYPOTHALAMUS. Neurophysin I is associated with oxytocin and neurophysin II is associated with vasopressin in their respective precursors and during transportation down the axons to the neurohypophysis (PITUITARY GLAND, POSTERIOR).

Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete.

A hypothalamic tripeptide, enzymatic degradation product of OXYTOCIN, that inhibits the release of MELANOCYTE-STIMULATING HORMONES.

More From BioPortfolio on "Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor"

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Searches Linking to this Trial